Published in J Immunol on December 01, 2000
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med (2011) 4.02
Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res (2007) 3.76
The role of NKT cells in tumor immunity. Adv Cancer Res (2008) 2.05
Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev (2009) 1.68
Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med (2001) 1.66
Exosomes as a tumor immune escape mechanism: possible therapeutic implications. J Transl Med (2008) 1.28
Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions. Cell Cycle (2010) 1.22
Signaling pathways involved in MDSC regulation. Biochim Biophys Acta (2014) 1.12
STAT6 expression in glioblastoma promotes invasive growth. BMC Cancer (2011) 1.05
Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood (2013) 1.02
Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo. J Immunol (2008) 1.01
Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defenses. Semin Cancer Biol (2012) 0.92
DNA methylation regulates constitutive expression of Stat6 regulatory genes SOCS-1 and SHP-1 in colon cancer cells. J Cancer Res Clin Oncol (2009) 0.85
Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction. J Immunol (2013) 0.79
The role of T helper cell differentiation in promoting nerve allograft survival with costimulation blockade. J Neurosurg (2010) 0.79
Interleukin-4 up-regulates mouse mammary tumor virus expression yet is not required for in vivo virus spread. J Virol (2001) 0.78
Differential IL-4/Stat6 activities correlate with differential expression of regulatory genes SOCS-1, SHP-1, and PP2A in colon cancer cells. J Cancer Res Clin Oncol (2008) 0.75
Anti-STAT6 CTL activity in Stat6 (-/-) mice: A cautionary tale. JAKSTAT (2013) 0.75
Behavior of the P1.HTR mastocytoma cell line implanted in the chorioallantoic membrane of chick embryos. Braz J Med Biol Res (2013) 0.75
Tumor-related interleukins: old validated targets for new anti-cancer drug development. Mol Cancer (2017) 0.75
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol (2010) 5.91
Helper T cell differentiation is controlled by the cell cycle. Immunity (1998) 5.71
Blocked Ras activation in anergic CD4+ T cells. Science (1996) 2.64
Differential regulation of murine T lymphocyte subsets. Annu Rev Immunol (1993) 1.94
IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol (2010) 1.76
Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells. Proc Natl Acad Sci U S A (2000) 1.68
B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Exp Med (1998) 1.62
Differential function of intestinal intraepithelial lymphocyte subsets. J Immunol (1992) 1.51
IL-6 inhibits the tolerogenic function of CD8 alpha+ dendritic cells expressing indoleamine 2,3-dioxygenase. J Immunol (2001) 1.46
Phenotypic and functional analysis of murine CD3+,CD4-,CD8- TCR-gamma delta-expressing peripheral T cells. J Immunol (1989) 1.39
Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol (1998) 1.31
CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. J Immunol (2001) 1.25
Murine hepatic accessory cells support the proliferation of Th1 but not Th2 helper T lymphocyte clones. J Exp Med (1989) 1.22
Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans. Mucosal Immunol (2009) 1.20
Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J Immunol (1996) 1.14
IFN-gamma inhibits presentation of a tumor/self peptide by CD8 alpha- dendritic cells via potentiation of the CD8 alpha+ subset. J Immunol (2000) 1.10
Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J Immunol (1996) 1.09
Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res (2001) 1.09
From defined human tumor antigens to effective immunization? Immunol Today (1995) 1.08
Positive regulatory role of IL-12 in macrophages and modulation by IFN-gamma. J Immunol (2001) 1.07
Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice. J Immunol (1997) 1.04
Mechanisms of CTLA-4-Ig in tolerance induction. Curr Pharm Des (2006) 1.03
Intranasally delivered siRNA targeting PI3K/Akt/mTOR inflammatory pathways protects from aspergillosis. Mucosal Immunol (2009) 1.03
B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells. J Immunol (1998) 1.01
Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int Immunol (2001) 1.00
The immune system as anti-tumor sentinel: molecular requirements for an anti-tumor immune response. Crit Rev Oncog (1999) 0.99
CD28 is not required for c-Jun N-terminal kinase activation in T cells. J Immunol (2001) 0.98
Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol (1999) 0.98
The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int J Cancer (1997) 0.96
Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J Immunol (2000) 0.96
Differential activation of Th1 and Th2 CD4+ cells by murine brain microvessel endothelial cells and smooth muscle/pericytes. J Immunol (1993) 0.96
Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol (2004) 0.94
Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase. J Immunol (2001) 0.94
The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen. J Urol (2001) 0.92
Antigen-specific blockade of T cells in vivo using dimeric MHC peptide. J Immunol (2001) 0.89
Control of T lymphocyte signal transduction through clonal anergy. J Mol Med (Berl) (1996) 0.86
Liver of MRL/lpr mice contain interleukin-4-producing lymphocytes and accessory cells that support the proliferation of Th2 helper T lymphocyte clones. Eur J Immunol (1992) 0.86
CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide. Eur J Immunol (1995) 0.86
Transplantation and the CD28/CTLA4/B7 pathway. Transplant Proc (2001) 0.83
Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells. Bone Marrow Transplant (2004) 0.83
The p815 mastocytoma tumor model. Curr Protoc Immunol (2001) 0.83
Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant (2005) 0.83
Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12. Int J Cancer (1999) 0.82
Peripheral survival of naïve CD8+ T cells. Apoptosis (2005) 0.81
Biochemical analysis of activated T lymphocytes. Protein phosphorylation and Ras, ERK, and JNK activation. Methods Mol Biol (2000) 0.81
Rational development of tumour antigen-specific immunization in melanoma. Ther Immunol (1995) 0.81
Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int J Cancer (1996) 0.80
Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer (1999) 0.80
Targeting metabotropic glutamate receptors in neuroimmune communication. Neuropharmacology (2012) 0.79
Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL. Eur Cytokine Netw (1999) 0.78
Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells. Int Immunol (1997) 0.78
IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. J Immunol (1996) 0.78
Multiple point mutations in an endogenous retroviral gene confer high immunogenicity on a drug-treated murine tumor. J Immunol (1995) 0.77
Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma. J Urol (2001) 0.76
Cytotoxic T lymphocyte antigen 4-immunoglobulin G is a potent adjuvant for experimental allergen immunotherapy. Clin Exp Immunol (2013) 0.75
Polymyositis with respiratory muscle weakness requiring mechanical ventilation in a patient with metastatic thymoma treated with octreotide. Ann Oncol (1999) 0.75
Novel pharmacological strategies in the treatment of life-threatening cytomegalovirus infections. Clinical experience with continuous infusion 9-(1,3-dihydroxy-2-propoxymethyl) guanine. Ann N Y Acad Sci (1990) 0.75
Regulation of anti-immunoglobulin-induced B lymphoma growth arrest by transforming growth factor beta 1 and dexamethasone. Int Immunol (1991) 0.75
Serum and urinary isoflavonoids and their metabolites in elderly men on diets supplemented with beverages containing untreated and alcohol-extracted soy protein. J Med Food (1999) 0.75
Diagnosis and treatment of mycoplasma-contaminated cell cultures. Curr Protoc Immunol (2001) 0.75